Evidence map›Paper›PMID 33876953›Full record

ArticleThe CRISPR journal2021

Optimizing Integration and Expression of Transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X-Linked Agammaglobulinemia.

David H Gray, Isaac Villegas, Joseph Long, Jasmine Santos, Alexandra Keir, Alison Abele, Caroline Y Kuo, Donald B Kohn

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The CRISPR journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Precision T cell correction platform for inborn errors of immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  4. Article
  5. Article
  6. Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Towards gene therapy for IPEX syndrome.European journal of immunology · 2022
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

David H GrayMolecular Biology Institute, University of California, Los Angeles, Los Angeles, California, USA; University of California, Los Angeles, Los Angeles, California, USA.
Isaac VillegasDepartment of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA; Departments of University of California, Los Angeles, Los Angeles, California, USA.
Joseph LongDepartment of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA; Departments of University of California, Los Angeles, Los Angeles, California, USA.
Jasmine SantosBioengineering, University of California, Los Angeles, Los Angeles, California, USA.
Alexandra KeirMolecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California, USA.
Alison AbeleMicrobiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
Caroline Y KuoDepartment of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA; Departments of University of California, Los Angeles, Los Angeles, California, USA.
Donald B KohnDepartment of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA; Departments of University of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-1840-6087
University of California, Los Angeles · US

Funding

UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
IRACDA - The New York Consortium for the Advancement of Postdoctoral Scholars (NY CAPS)Phase IIK12GM102778 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Carol A. Carter, Karian Janice Wright · 2012 to 2026
$13.1M
NIGMS NIH HHS T32 GM007185
6 · The paper itself

Abstract

X-linked agammaglobulinemia (XLA) is a monogenic primary immune deficiency characterized by very low levels of immunoglobulins and greatly increased risks for recurrent and severe infections. Patients with XLA have a loss-of-function mutation in the Bruton's tyrosine kinase (

Indexed as

CRISPR-Cas SystemsGenetic TherapyAgammaglobulinaemia Tyrosine KinaseAgammaglobulinemiaB-LymphocytesCodonDNA, ComplementaryGene EditingGenetic Diseases, X-LinkedGenetic LociHumansIntronsK562 CellsMutationOrganisms, Genetically ModifiedAgammaglobulinaemia Tyrosine KinaseBTK protein, humanCodonDNA, Complementary

Identifiers

PMID33876953
PMCPMC8336228
OpenAlexW3154312342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.